Nicotinamide phosphoribosyltransferase (NAMPT) has been investigated as a target for oncology because it catalyzes a rate-limiting step in cellular energy metabolism to produce nicotinamide adenine dinucleotide. Small molecule inhibitors of NAMPT have been promising drug candidates but preclinical development has been hindered due to associated retinal toxicity. Here we demonstrate that larval zebrafish can predict retinal toxicity associated with this mechanism revealing an attractive alternative method for identifying such toxicities. Zebrafish permit higher throughput testing while using far lower quantities of test article compared with mammalian systems. NAMPT inhibitor-associated toxicity manifested in zebrafish as a loss of response to visual cues compared with auditory cues. Zebrafish retinal damage associated with NAMPT inhibitor treatment was confirmed through histopathology. Ranking 6 NAMPT inhibitors according to their impact on zebrafish vision revealed a positive correlation with their in vitro potencies on human tumor cells. This correlation indicates translatable pharmacodynamics between zebrafish and human NAMPT and is consistent with on-target activity as the cause of retinal toxicity associated with NAMPT inhibition. Together, these data illustrate the utility of zebrafish for identifying compounds that may cause ocular toxicity in mammals, and, likewise, for accelerating development of compounds with improved safety margins.
Studies uncovering the reliance of tumor cells on distinct energy metabolism pathways have delivered novel and promising cancer targets (Boroughs and DeBerardinis, 2015; Marin de Mas et al., 2014) . Nicotinamide phosphoribosyltransferase (NAMPT) is overexpressed in many tumor cells which rely upon it for the production of nicotinamide adenine dinucleotide (NAD), a key metabolite for sustaining energy metabolism. This makes NAMPT an attractive drug target for oncology indications (Bi and Che, 2010; Sampath et al., 2015) . However, recent reports have demonstrated side effects associated with NAMPT inhibitor treatments in nonneoplastic tissues such as platelets, skin, gastrointestinal tract, and retina; these toxicities have arrested the development of promising therapeutics that use this mechanism (Sampath et al., 2015; Zabka et al., 2015) .
NAMPT is expressed in all nonneoplastic tissues surveyed to date from dog, rat, and human (Duarte-Pereira et al., 2016; McGlothlin et al., 2005; Samal et al., 1994; Zabka et al., 2015) and is an essential gene in mice, as evidenced by nonconditional and conditional knockout models (Zhang et al., 2017) . Although NAMPT is apparently ubiquitously expressed, some tissues, like retina, are more sensitive to NAMPT inhibition. This may be due to a relatively high reliance on NAMPT for NAD synthesis. NAD can be synthesized by 2 major pathways which use different substrates (Bogan and Brenner, 2008; Wilsbacher et al., 2017) .
One pathway is driven by NAMPT activity, the other relies on nicotinic acid phosphoribosyltransferase (NAPRT1). Depending on relative gene expression and substrate availability, tissues may differ in their reliance on NAMPT versus NAPRT1 for NAD synthesis. Quantitative PCR analysis of NAMPT and NAPRT1 transcripts in 8 rat tissues revealed that retina expressed relatively high levels of NAMPT, and had a NAMPT-to-NAPRT1 ratio greater than 1, suggesting a higher reliance on NAMPT for NAD synthesis in retina .
Recently we reported on the pharmacology of substrate and nonsubstrate inhibitors of NAMPT (Curtin et al., 2017; Wilsbacher et al., 2017) . Nonsubstrate inhibitors are not phosphoribosylated by NAMPT, making them a new class of inhibitors. Given the reported reliance of mouse vision on NAMPT activity (Lin et al., 2016) and the retinal toxicity associated with NAMPT inhibition , we investigated effects on larval zebrafish vision in early toxicological assessment of 1 substrate and 6 nonsubstrate NAMPT inhibitors. This investigation allowed for in vivo assessment of retinal toxicities on an in vitro scale.
Zebrafish offer opportunities for higher throughput experiments and lower costs compared with mammalian models owing to their ease of handling, rapid development, and small size. The latter attribute is especially demonstrated by larval zebrafish. Larval zebrafish can survive for multiple days in small volumes of static water. As such, hundreds of larval zebrafish can be tested in simple multiwell plate formats using very small quantities of test compound. Where translatable biology is anticipated, this is an attractive platform for testing candidate compounds in early drug discovery; typically, large amounts of early discovery compounds are not readily available.
For zebrafish, visual development is rapid, with the behavior of free-swimming larvae becoming heavily reliant on visual cues by 4 days postfertilization (dpf) (Easter and Nicola, 1996) . By 3 dpf, although the retina is not yet fully mature, retinal neurogenesis is essentially complete, major retinal cell classes are detectable and organized into distinct layers, and ganglion cell axons have innervated the optic tectum (Avanesov and Malicki, 2010) . Mammalian and zebrafish retinal organization, cell composition and gene expression patterns are similar (Avanesov and Malicki, 2010; Goldsmith and Harris, 2003; Slijkerman et al., 2015) . All major cell types and tissue layers in mammalian retina are represented in zebrafish retina, including retinal nerve fiber layer, ganglion cell layer, inner plexiform layer, inner nuclear layer, outer plexiform layer, outer nuclear layer, inner and outer segments, and pigmented epithelium (Avanesov and Malicki, 2010; Slijkerman et al., 2015) . Zebrafish have color vision like that of humans, and their retina is correspondingly conedense. Alternatively, the mouse and rat, being nocturnal animals, have relatively fewer cones and poor color vision (Goldsmith and Harris, 2003) .
Structural or cellular attributes of zebrafish retinas distinguishing them from mammalian retinas are that they lack a cone-rich area, have more cones than rods, possess ultravioletsensitive cones in addition to those for red, green, and blue, and have double cones composed of a principle (red) and an accessory (green) cone (Slijkerman et al., 2015) . Perhaps the most significant difference between zebrafish and mammalian retina, and pertinent to using zebrafish to model retinal injury, is the regenerative capacity of zebrafish retina. This capacity, found in developing and mature retinas, relies on Mü ller glial cells which respond to injury by dividing to produce a retinal progenitor capable of generating all major retinal neuron types (Wan and Goldman, 2016) .
Retinal angiogenesis and vasculature are similar between zebrafish and mammals. In both model systems, angiogenesis from a central retinal artery forms the retinal vasculature, and early hyaloid vasculature associated with the lens diminishes with age, leaving vasculature associated with the ganglion cell layer that persists into adulthood (Alvarez et al., 2007) . In mature mammalian retinas, however, vessels branch to form intraretinal capillaries that nourish the inner and outer plexiform layers. These capillaries are not present in adult zebrafish; presumably the thinner zebrafish retina needs fewer capillaries and can rely on diffusion from the surface (hyaloid and choroid) vessels (Alvarez et al., 2007) .
Taken together with their ease of handling, rapid development, and small size, translational retinal biology gives the zebrafish an advantage as a highly relevant species for modeling genetically or pharmacologically driven retinal degeneration, as evidenced in the literature (Deeti et al., 2014; Morris, 2011) . Here we report the utilization of zebrafish larvae to assess retinal toxicities associated with NAMPT inhibitor treatment.
MATERIALS AND METHODS
Animal husbandry. Adult wild-type zebrafish (Danio rerio) were housed in a continual-flow housing system (Tecniplast ZebTEC, Buguggiate, VA, Italy). Water conditions were maintained by a centralized monitoring system and held constant at: temperature 28 C 6 1 C, pH 7.5 6 0.5, conductivity 950 microsiemens.
General husbandry and breeding were conducted using standard conditions (Westerfield, 2000) . Embryos were collected from breeding tanks 2-3 h after removing the male/female separation barrier. Larval fish were housed in 10 cm petri dishes (50 fish/50 ml) and kept in an incubator on a 14: 10 light: dark cycle at 28 C 6 1 C. Larval fish water (pH ¼ 7 6 0.5) was 60 lg/ml Compounds. Seven small molecule inhibitors of human NAMPT were tested for their effects on zebrafish vision (Figure 1 ). Only one of these compounds, the azaisoindoline A-1326133, is a phosphoribosylated substrate of NAMPT, while the other 6 compounds are members of the isoindoline series and are nonsubstrate inhibitors of NAMPT (Curtin et al., 2017; Wilsbacher et al., 2017) . These seven compounds were chosen because, as a group, they exhibit a range of in vitro inhibitory potencies on human tumor cell proliferation ( Figure 1 ) and therefore represent a relevant test set to explore a potential range of effects on zebrafish vision.
Maximum tolerated dose. To determine an appropriate concentration range for each test compound in the vision assays, a maximum tolerated dose (MTD) study was performed. Compound solutions were prepared as described below for vision assays. The 7-concentration dilution series for each compound ranged from 0.3 to 300 lM at 1 =2-log intervals. To prevent clutch-specific or genetic deficiencies from impacting the identification of treatment-specific effects, all treatments within a given experiment, including vehicle control, contained equal numbers of fish from the same clutches. Five dpf zebrafish were exposed to treatments for 48 h at 28 C 6 1 C in 24-well plates (6 fish per well). Each well contained 2 ml of a different concentration of the test compound dilution series, and each plate contained a vehicle-treated (0.3% dimethyl sulfoxide [DMSO]) control group. Fish were then evaluated for survival using a dissecting stereoscope or compound microscope. Mortality was confirmed visually by absence of heartbeat. Sublethal toxicity was qualitatively assessed by lack of startle response to a tactile stimulus (gentle touch on the dorsal surface with a fine pipette tip) or the presence of a gross morphological abnormality, such as pericardial or whole body edema. The MTD was defined as the highest concentration that did not cause death and did not induce sublethal toxicity.
Vision assays. Test compounds were solubilized as 300Â stocks in DMSO and administered in larval fish water at 3 concentrations: high (same as MTD), middle ( 1 =2-log below MTD), and low ( 1 =2-log below middle) (see Table 1 ). The DMSO concentration was 0.3% for each treatment, including the vehicle treatment.
Compound solution pH was measured and, when necessary, titrated to pH 7.0 using sodium bicarbonate or hydrochloric acid. As was done for the MTD studies, all treatments within a given experiment, including vehicle control, contained equal numbers of fish from the same clutches. Treatments were administered to fish starting on day 5 postfertilization for a total of 72 h; the dosing solution was replenished with fresh dosing solution after the first 48 h, to maintain continued exposure levels for the final 24 h. Twelve fish were used in each treatment group, being held together in a single well of a 12-well plate in a volume of 2 ml. Each compound was accompanied by a designated vehicle-treated group of 12 fish.
Startle response. Startle response in larval zebrafish is defined as any abrupt movement occurring within 2 s of a light or sound stimulus (Bhandiwad et al., 2013; Portugues and Engert, 2009; Scott et al., 2016) . After the 72-h treatment with the experimental molecules, startle responses to light and sound stimuli were quantified using a behavioral tracking system as follows. Although still in the 12-well plate used for dosing, the fish were acclimated to the dark for 5 min in a behavioral tracking device (ZebraBox; Viewpoint, Lyon, France). Then ensued three 5-s periods of light (20% intensity), each separated by 1 min of darkness. The light remained on after the third period for the remainder of the assessment, during which fish were exposed to three 40 ms of sound (660 Hz) each separated by 1 min of silence. The total activity for each treatment was quantified using ZebraLab software (Viewpoint). An activity integral, representing the sum of all image pixel changes detected within the well for each 1 s period of the program was computed and recorded by the software.
To generate a startle response metric, the average activity per second during the 25 s immediately prior to a stimulus was subtracted from the activity ensuing during the 1-s period following the start of the stimulus. Thus the value represents the startle response as a difference from background for each stimulus. These data are expressed as % vehicle-treated response.
Optomotor response. After recording startle responses, fish were tested in an optomotor response (OMR) assay. This assay relies on directional swimming prompted by visual cues (stripes of contrasting color, moving independently of the subject in a constant direction for a prescribed period of time) (Berghmans et al., 2008, Maaswinkel and Li, 2003) . Healthy fish swim in the same direction as the pattern moves. We conducted the OMR assay as follows. Fish treated with vehicle, low, middle, and high doses for a given test compound were transferred to a clear acrylic manifold into separate parallel troughs, each measuring 26 Â 1 Â 1 cm. These troughs contained 15 ml of treatment The highest dose for each compound was the MTD.
solution to maintain exposure. The manifold was placed on a computer monitor. A visual stimulus (Carpetbones; https://car petbones.itch.io/zot; last accessed October, 2017) was displayed, consisting of black and white alternating stripes, 2 cm wide, spanning the monitor, and moving perpendicular to the length of the troughs at a speed such that the black/white pattern replaced itself every 2.5 s (stripes moving at 1.6 cm/s). The stimulus first moved 1 direction for 3 min, after which fish located in the final 1 =4 (6.5 cm) of the trough were counted. Then the stimulus moved in the opposite direction for 3 min, and fish were counted in the opposite 1 =4 of the trough. These trials were repeated 2 more times for a total of 6 trials, 3 each direction. OMR data are presented as the percent of fish found in final 1 =4 of trough (ie, passing the assay), expressed as an average of the 6 trials. Comparison to the vehicle group was performed via a Student's t-test of the 6 trials. In order to fail the assay, a group had to have a pass average significantly lower than that of the vehicle group, and below 52.3%. This value (52.3%) represents the lower 10th percentile of 126 trials of vehicle groups tested on this platform. The use of this qualification rule is estimated to keep the false positive rate of this assay at or below 10%. An assay was invalidated if the vehicle group pass average did not exceed 52.3%.
Histopathology. After the OMR assay, 3 fish from each treatment, as well as from the vehicle control group were euthanized in 4 C water and transferred individually to 1.5 ml conical vials containing 0.5 ml of 10% neutral buffered formalin. These fish were kept at room temperature (RT) at least overnight, and then prepared for sectioning as follows. Fish were embedded cranial side down in a 2% agarose matrix to maintain their orientation as well as to enable processing for paraffin embedding. These fish were then processed through a series of graded alcohol and xylene concentrations, and infiltrated with melted paraffin following standard histology processing protocol. Whole fish were embedded in paraffin cranial side down to enable microtomy sectioning of the head within a transverse plane. Serial sections, 4 mm thick, were taken from rostral to caudal to capture all features of the eye. The sections were placed on positive charged glass slides and routine H&E staining was performed. Sections were examined using an Olympus (Tokyo, Japan) BX41 light microscope and images were acquired using an Olympus DP72 camera. Larval fish treated with 30 mM A-1326133 for 3 days were collected for transmission electron microscopy (TEM) of the retina. This compound/dose was chosen for TEM assessment of retinal damage based on results from the initial experiment which tested only A-1326133 and A-1293201. In that experiment, 30 mM A-1326133 was the most toxic treatment on zebrafish vision and had the most evident retinal findings by H&E staining. After euthanasia in 4 C water, treated fish were collected, along with vehicle-treated fish individually into 1.5 ml vials containing 0.5 ml of 1 =2 strength Karnovsky's fixative in 0.1 M Sorensen's phosphate buffer (SPB) pH 7.2-7.4 and stored at 4 C for at least 24 h. The fish were then washed in 2 exchanges of 0.1 M SPB pH 7.3 prior to postfixing in 1% osmium tetroxide in 0.1 M SPB for 1 h at RT. Osmium tetroxide was removed and replaced with 0.1 M SPB, which was replaced with deionized water (15 min each at RT). Fish were then dehydrated at RT through a graded ethanol series, 50%, 75% (one exchange each for 15 min), 95% (two 15 min exchanges), and 100% (two 10 min exchanges). Ethanol was cleared using propylene oxide (two 10 min exchanges), followed by overnight incubation in 1:1 propylene oxide: epoxy resin, which was replaced with 100% epoxy resin. Fish were embedded in flat silicon molds in 100% epoxy resin and polymerized at 60 C for 4 days.
Semi-thin 1 mm sections of the fish were prepared using an EM UC6 ultra microtome (Leica Microsystems, Wetzlar, Germany) and stained on glass slides with 1% toluidine blue/sodium borate. Ultrathin approximately 80 nm sections were prepared from selected blocks based on evaluation of the toluidineblue slides, collected on 3 mm, 200 mesh, Cu/Rh grids and stained with 2% methanolic uranyl acetate followed by Reynold's lead citrate. Ultrathin sections were viewed and images were acquired using a JEM1400 TEM (JEOL, Tokyo, Japan) operated at 80 kV equipped with an AMT XR-41 digital camera (Advanced Microscopy Techniques, Woburn, MA, USA).
Drug analysis. After the OMR assay, 3 fish from each treatment group were euthanized in 4 C water, rinsed in 50 ml of larval fish water 2 times and placed together into a preweighed vial. The majority of water was then carefully removed and the vial placed in dry ice. After determining the mass of the 3 fish, deionized water (300 ml) was added and they were homogenized using an Omni Bead Ruptor 24 (Omni International, Kennesaw, GA, USA). An aliquot of fish homogenate and set of standards were pipetted into a 96-well plate and subjected to protein precipitation extraction on Microlab Star robot (Hamilton Robotics, Franklin, MA, USA). The dosing solutions were likewise prepared. A dilution series was made to generate a range of standards from 1000 to 0.1 ng/ml. The acetonitrile, containing 6 reference compounds (12.5 nM verapamil, 1000 nM dexamethasone, 200 nM diclofenac, 250 nM carbutamide, 125 nM lidocaine, and 100 nM tolbutamide) as internal standards, was used as an organic solvent to precipitate out all the biological proteins from fish and dosing solution. Supernatant from protein precipitation was transferred into mass spectrometry plates and diluted with the mobile phase of the liquid chromatographymass spectrometry (LC-MS) column. The liquid chromatography analysis was performed using reverse phase or HILIC (hydrophilic interaction liquid) chromatography in either positive or negative ion mode using gradient elution. The tandem mass spectrometry analysis was carried out on SCIEX (Framingham, MA, USA) triple quadrupole mass spectrometer with an electrospray or atmospheric pressure ionization interface. Data acquisition and evaluation were performed using Analyst software (SCIEX). For comparing drug levels of a NAMPT inhibitor in the eye with that of the rest of the body, 10 month old zebrafish (n ¼ 3) were treated with 30 mM A-1326133 in fish system water (pH 7.0, 920 mS, 28 C), or vehicle (system water plus 0.3% DMSO) for 3 days. After this period, following euthanasia in 4 C water, the eyes were dissected from the remainder of the body. Drug analysis was performed as described above, treating eyes and body separately.
Calculation of zebrafish Vision Loss 50. To allow for comparing toxic potencies of test compounds on zebrafish vision, we devised a zebrafish % Vision Loss-50 index (VL50). The VL50 is a prediction of the amount of test compound required in the larval fish to drive a 50% deficit in the startle response to light as compared with vehicle-treated fish. The VL50 was derived by the following method: startle responses to light (as % vehicle) were plotted as a function of the amount of compound measured in the fish (pmoles per larva) for each dose level. A linear regression was generated for each compound using those points, and including a point representing vehicle (100% and 0 pmoles/larva). Using that regression equation, the value of x where y ¼ 50 was calculated. This represents the level of compound in the fish predicted to drive a 50% deficit in the startle response to light, and is the VL50.
Alignment and 3D modeling of human and zebrafish NAMPT activation site. A structural model of the zebrafish NAMPT protein was constructed from the predicted sequence recorded with NCBI reference number XP_002661386 using the homology modeling module within the Maestro suite (Schrodinger, New York, NY, USA). The crystal structure of human NAMPT in complex with inhibitor A-1326133 (pdb code 5U2N) was used as basis for the model of the protein structure. The final image was prepared using the program PyMOL (Schrodinger).
RESULTS

Drug Analysis and MTD
The average solubility for all treatments analyzed was 50.4% (619.3). Solubility was calculated by dividing the dose solution concentration, as measured by LC-MS (data not shown), by the target concentration for each treatment. All NAMPT inhibitors were well absorbed by the larval fish. The average absorption for all treatments was 1.9 Â 10 À6 (mmol per larva/mM in dose solution). For perspective, absorption values from all treatments in this report were in the upper 25% of that for 43 drugs in our prior report (Cassar et al., 2017) . Compound levels detected in larvae were dose-dependent for all 7 compounds; increasing the dose increased levels in the fish (Table 1) . These data were used to build dynamic relationships between compound exposure and behavioral endpoints, and for calculating VL50s. MTDs ranged from 3 to 300 mM. For each compound, the highest dose listed in Table 1 was the MTD. Concentrations above the MTD resulted in mortality of ! 2 fish and/or in loss of response to touch for ! 3 fish (out of 6). Loss of response to touch was considered a severe finding since those fish would likely not respond to a visual stimulus, regardless of retinal function. As such, the MTD is the concentration where at least 5 of 6 fish survived, and at least 4 of 6 responded to touch. Besides the loss of response to touch, there were no other sublethal toxicities noted. Providing a tissue distribution basis for vision liability, levels of A-1326133 in the eyes of adult fish were, on average, 4.9 (6 2.3) times higher than that detected in the rest of the body (mass/volume), demonstrating that this compound can accumulate in the eye of zebrafish.
Vision Assays
Startle response. Among vehicle-treated groups, the standard deviations for startle responses to light and sound, calculated as percent of the average, were 67% and 52%, respectively (data not shown). Expressing data from compound-treated groups as percent of vehicle response allowed for detecting dose-related effects despite this high variability. Startle response to light was impacted by NAMPT inhibitors in a concentration-dependent manner (Table 1) . For 6 of the 7 compounds, the MTD ablated the startle response to light. Response to sound for the same groups was not ablated (Table 1, Figure 2 ), indicating that the observed deficits in response to light are likely caused by loss of vision rather than by a general effect on mobility and/or the central nervous system. The only compound that did not ablate the startle response to light was A-1325236.
The exposure dependent loss in vision allowed for estimating the exposure necessary to drive a 50% loss in vision (VL50) for 6 of the 7 compounds. A-1325236 was not included because fish dosed with the MTD did not lose vision, maintaining a response to light. For the other 6 compounds, comparing VL50s to in vitro potencies on a human prostate cancer cell line (PC3) (see Wilsbacher et al., 2017 for methods) revealed a positive correlation (R 2 ¼ 0.45, Figure 3 ). This suggests an on-target mechanism for vision liabilities associated with NAMPT inhibition and indicates translatable pharmacology for these compounds between zebrafish and human. Comparison of the model of A-1326133 interacting with zebrafish NAMPT to the crystal structure of the same compound bound to human NAMPT reveals a high conservation of residues in the inhibitor binding site and suggests that amino acid differences in the zebrafish NAMPT are not likely to interfere with binding ( Figure 4 ).
Optomotor response. Poor performance in the OMR correlated with NAMPT inhibitor exposure (Table 1) . Failure rates were high, reflecting the relatively high doses tested (in the vicinity of the MTD). The OMR proved to be more sensitive to drug effects than that of the startle response. That is, some of the same groups with robust startle responses to light (!vehicle response) failed the OMR ( Figure 5 ).
Visual Background Adaptation, Histopathology, and Electron Microscopy Larval fish dosed with high levels of some of the NAMPT inhibitors appeared grossly darker than fish in vehicle-treated and lower dosed cohorts. The dark appearance was derived from increased visible melanin in the skin (Figure 6 ). In the melanophores of larval zebrafish, melanin-filled vesicles (melanosomes) are dispersed in response to low light levels, engendering a darkened camouflage; this is referred to as visual background adaptation (Logan et al., 2006) . The observations of increased pigmentation in NAMPT-inhibitor-treated fish were made during lights-on periods, when vehicle treated fish were sparsely pigmented (Figure 6 ). Loss of proper visual background adaptation in zebrafish has been associated with loss of retinal ganglion cells (Kay et al., 2001) . Indeed, for fish dosed with 5 of 7 NAMPT inhibitors, examination of H&E stained tissue sections revealed retinal degeneration characterized by decreased numbers of nuclei in the ganglion cell layer and inner nuclear layer (Figure 7) . Increased clear space in these layers was attributed to loss of nuclei and disorganization. Reduced numbers of cell layers resulted in diminished height, collapse, and disorganization of these layers. Clear spaces within the inner plexiform and nerve fiber layers were increased and considered related to fewer axons and dendrites in these areas secondary to nuclei loss. The compounds not associated with such lesions were A-1466391 and A-1325236 (see "Discussion" section).
Transmission electron micrographs of slides prepared from larval fish dosed with 30 mM A-1326133 revealed decreased cell density and neuronal death in the inner nuclear and retinal ganglion layers (Figure 7) . The neuronal death was characterized by condensation and fragmentation of chromatin, which is consistent with apoptosis. Apoptotic bodies (granular electron dense nuclear remnants) were present in the ganglion cell, inner plexiform and inner nuclear layers. Vacuolation was also observed in the inner plexiform layer associated with this NAMPT inhibitor treatment, consistent with loss of cytoplasmic processes.
Two of the seven compounds from this report (A-1293201 and A-1326133) were tested in mammals. Similar to the NAMPT inhibitor associated toxicity reported by Zabka et al. (2015) , these compounds caused retinal damage. For A-1326133, retinal toxicity was observed in dogs (data not shown) and rats. Figure  8 shows retinal damage in a rat dosed with 10 mg/kg A-1326133 once a day for a total of 8 days; the dose regimen, projected to provide efficacy while minimizing toxicity, was 4 days on, 3 days off, and 4 days on treatment. The damage is characterized by loss of photoreceptor nuclei and segments, loss and collapse of the outer plexiform layer and rarefaction and vacuolation of the inner plexiform layer. For A-1293201, similar findings were observed in corresponding cell layers of dog retina (data not shown).
DISCUSSION
Monitoring drug solution concentrations and exposure levels in larval fish experiments can help interpret biological and behavioral endpoints (Cassar et al., 2017) . Dose-related increases in exposure for NAMPT inhibitors were associated with total loss of response to visual cues at the MTD for most compounds. For each of the 7 compounds, exposure at the MTD was 2-4 times higher than that of the next lower dose (calculated from Table  1 ). This observation highlights the dose-exposure-toxicity relationship for these NAMPT inhibitors on retina and demonstrates the utility of this assay for prioritizing safe compounds above more toxic ones.
Factors that can influence relative toxicity include drug metabolism, potency on zebrafish NAMPT, as well as dose range, exposure, and biodistribution in zebrafish. Of these factors, only dose range and exposure were measured in these experiments. Vacuolation, or clear spaces (red arrows), are observed in the nerve fiber, ganglion cell, inner plexiform and inner nuclear layers associated with cell loss. NF, nerve fiber layer; GC, ganglion cell layer; IP, inner plexiform layer; IN, inner nuclear layer; OP, outer plexiform layer; PR, photoreceptor layer.
Having these values, and knowing relative potencies on PC3 cells, allows for further interpretation of results. For example, A-1325236 appears safer than the others because it did not ablate response to light at its MTD. However exposure may have been too low given this compound's relative low potency on inhibiting PC3 tumor cell growth. Only A-1293201 and A-1343741 have weaker potencies on PC3 compared with A-1325236 ( Figure 1 ) and response to light was ablated by those 2 compounds only at higher levels than that achieved by A-1325236 (Table 1) . Still, A-1459319, which has similar potency to A-1325236, ablated response to light at an exposure equal to that achieved by A-1325236. Some unexamined factors that could be playing a role in this discrepancy are relative potencies on zebrafish NAMPT and differences in biodistribution (eye penetration).
The only compound for which eye tissue concentrations were measured in this report was A-1326133. Due to the small size of larval zebrafish, this experiment was conducted in adult zebrafish. The high levels measured in the eyes versus the rest of the body for A-1326133, indicate that it accumulates in the eye. A-1326133 is phosphoribosylated by NAMPT. This change increases the polarity of the compound and decreases its ability to penetrate the cell membrane. In tissues with high NAMPT expression, substrate inhibitors of NAMPT (like A-1326133) may accumulate, being confined to the cell once phosphoribosylated. If zebrafish, like rat, express high levels of NAMPT in retinal cells, this could explain the higher concentrations of A-1326133 in the eye compared with the systemic exposure. The other compounds that caused vision loss and retinal damage may also accumulate in the eye, but perhaps to different extents. Comparing abilities of all compounds to penetrate zebrafish eyes may help interpret differences in toxic potency.
The limited data presented herein, suggests that nonsubstrate inhibitors of NAMPT, as a class, do not offer an advantage over the substrate inhibitor (A-1326133) in mitigating retinal toxicity. However, a fully informative comparison would require matched pairs of compounds differing only in the presence or absence of the aromatic nitrogen capable of being phosphoribosylated by NAMPT. Without such direct comparisons, a decision on the benefit of nonsubstrate inhibitors for alleviating toxicity cannot be reached.
The comparable relative potencies of these NAMPT inhibitors in preventing PC3 growth and causing retinal damage in zebrafish larvae, together with the predicted structural homology of the inhibitor binding sites, indicate translatable pharmacology between zebrafish and human NAMPT. These data also indicate that mammalian retinal toxicities reported with this pharmacology are driven by an on-target mechanism. Namely, NAMPT inhibition in retinal cells likely decreases NAD to intolerable levels and results in cell death due to energy depletion.
Aside from the inner plexiform layer, the retinal layers impacted in mammals (photoreceptor and outer nuclear) are not homologous with the layers impacted in zebrafish larvae (ganglion cells and inner nuclear). Reasons for this incongruity are unknown. Some possible reasons are: differences in NAMPT versus NAPRT1 expression among retinal cell types between the 2 models which has yet to be explored; differences in vascularization, since zebrafish unlike mammals do not have intraretinal capillaries (Alvarez et al., 2007) possibly explaining why those layers closest to retinal arteries in zebrafish are more susceptible; the stage of life, zebrafish larvae being at an earlier stage with a developing retina compared with adult mammals, which may cause differential energy requirements among cell layers; Images taken at similar locations within the retina (H&E, 40Â). GC, ganglion cell and nerve fiber layer; IP, inner plexiform layer; IN, inner nuclear layer; OP, outer plexiform layer; ON, outer nuclear layer; PS, photoreceptor segment layer; RPE, retinal pigmented epithelium. or from differences in dosing route, in-water dosing of zebrafish versus oral dosing of mammals.
It has been reported that apoptosis occurs in the ganglion cell layer and inner nuclear layer of larval zebrafish at low levels during early development (3-4 dpf) (Biehlmaier et al., 2001) . The studies reported herein were conducted starting at 5 dpf, and apoptosis was not observed in vehicle-treated age-matched larvae. This suggests that apoptosis observed in connection with NAMPT inhibitors was not development related.
It is unknown if retinal regeneration influenced the visual or histopathological results of our experiments. Our methods ensured continual exposure of the larvae to the test compounds throughout visual testing and up to the time of euthanasia, preventing a recovery period. Also, the duration of treatment used herein (72 h) is roughly the same time reportedly involved in cellular reprogramming and neuronal precursor generation (Gorsuch and Hyde, 2014; Kassen et al., 2007) . These conditions suggest that, if any, only minimal effects from regenerative activity might be expected on the observed toxicities of these compounds.
The OMR assay detected toxicity in treatment groups where the startle response was not impacted. This highlights the influence of locomotion on OMR performance; not only do the fish need to see the visual stimulus but they must have the ability to swim nearly as well as vehicle-treated fish for the duration of the assay. It is reasonable to speculate that NAMPT inhibition, impacting energy metabolism, may adversely affect swimming ability in fish, in addition to vision. The startle response, because it is a quick, reflexive action that does not rely on endurance, may indicate retinal function with more specificity than the OMR.
Retinal degeneration was noted for 5 of the 7 NAMPT inhibitors. No retinal lesions were noted for fish treated with A-1466391 or A-1325236. Unlike A-1325236, treatment with A-1466391 resulted in exposure-related vision loss. The possibility exists that retinal damage had ensued but was not evident with light microscopic examination in tissue sections captured from those fish. Impaired vision can occur in some retinal toxicities that impair electrophysiological function in absence of, or preceding, development of anatomical lesions (Ramos et al., 2011) .
Development of promising cancer therapies is often hampered by tissue specific toxicity. Retinal toxicity is a key toxic finding in preclinical testing of NAMPT inhibitors as reported here and elsewhere (Sampath et al., 2015; Zabka et al., 2015) . Anatomy and physiology of the zebrafish retina are well characterized (Avanesov and Malicki, 2010; Goldsmith and Harris, 2003; Slijkerman et al., 2015) . The many similarities in gene expression, cell composition, anatomical architecture, and function between zebrafish and mammalian retinas typify the conserved nature of the vertebrate eye. When translatable biology like this is anticipated, the zebrafish can be a powerful tool for drug development. This model offers significantly higher throughput and requires less test article than mammalian models. Zebrafish can be employed early in drug development to identify safer drug candidates, or to help discover successful mitigation strategies designed to alleviate the toxicity of promising chemotherapeutics on nontumor cells.
